Literature DB >> 6176754

[The elimination of hydroxyethyl starch 200/0.5, dextran 40 and oxypolygelatine (author's transl)].

H Köhler, H Zschiedrich, A Linfante, F Appel, H Pitz, R Clasen.   

Abstract

After withdrawal of 400 ml whole blood and subsequent infusion of 500 ml of a colloidal plasma substituent, the intravascular and renal colloid elimination was investigated in 40 test subjects. The individual colloidal solutions could no longer be demonstrated in the intravascular space after the following times: 10% hydroxyethyl starch 200/0.5 (anthrone method) after six weeks, 10% dextran 40 (anthrone method) after two weeks, 6% hydroxyethyl starch 200/0.5 (anthrone method) after four weeks and 5.5% oxypolygelatine (hydroxyproline method) after two days. Colloidal plasma substitutes are polydisperse solutions with various molecular weights and degree of hydroxyethylation and therefore, also have a large number of different elimination constants. With repeated application, the intravascular colloid concentration shifts in favour of the molecules with a longer half life which are difficult to eliminate. The elimination of the clinically employed dextran 40 and oxypolygelatine solution could be best described with an open two-compartment model. As a result of its greater heterogeneity, the elimination of the moderately high molecular weight hydroxyethyl starch 200/0.5 could only be characterized approximately even assuming three elimination constants. In the first four days, the hydroxyethyl starch 200/0.5 was more rapidly eliminated compared to dextran 40. However, subsequently a very much lower elimination from the intravascular space was found for about 3% of the administered hydroxyethyl starch 200/0.5. Oxypolygelatine was eliminated especially rapidly. Accordingly, the greatest renal clearance was found for oxypolygelatine, which showed a close relation to the molecular weight. On the other hand, a rapid elimination simultaneously is followed by a correspondingly lower volume effect.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6176754     DOI: 10.1007/BF01716806

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  29 in total

1.  THE RENAL EXCRETION OF LOW MOLECULAR WEIGHT DEXTRAN.

Authors:  G ARTRUSON; K GRANATH; L THOREN; G WALLENIUS
Journal:  Acta Chir Scand       Date:  1964-05

2.  THE RENAL CLEARANCE OF DEXTRAN OF DIFFERENT MOLECULAR SIZES IN NORMAL HUMANS.

Authors:  G ARTURSON; G WALLENIUS
Journal:  Scand J Clin Lab Invest       Date:  1964       Impact factor: 1.713

3.  [HISTOLOGICAL AND PHYSIOLOGICAL STUDIES ON RATS AFTER ADMINISTRATION OF THE PLASMA EXPANDER GELIFUNDOL].

Authors:  W GRIEM; G CZOK; K LANG
Journal:  Anaesthesist       Date:  1964-10       Impact factor: 1.041

4.  [On changes in structure and shape of the mitochondria. II. Disintegration and reorganization of chondrioma in uptake and degradation of macromolecular substances (dextran)].

Authors:  G GABLER
Journal:  Z Gesamte Exp Med       Date:  1961

5.  [Microdetermination of hydroxyproline with chloramine-T and p-dimethylaminobenzaldehyde].

Authors:  H STEGEMANN
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1958

6.  [Pharmacocinetics and dosage of dextran 40 in relation to renal function (author's transl)].

Authors:  H Köhler; W Kirch; D Höffler; P Koeppe
Journal:  Klin Wochenschr       Date:  1974-12-01

Review 7.  Determination of hydroxyproline.

Authors:  H Stegemann; K Stalder
Journal:  Clin Chim Acta       Date:  1967-11       Impact factor: 3.786

8.  [Formation of high-molecular aggregates between serum amylase and colloidal plasma substitutes (author's transl)].

Authors:  H Köhler; W Kirch; H J Horstmann
Journal:  Anaesthesist       Date:  1977-11       Impact factor: 1.041

9.  [Effect of kidney function on the elimination and action of colloidal plasma substitutes].

Authors:  H Köhler
Journal:  Fortschr Med       Date:  1979-10-25

10.  [Mathematical decription of the human intravascular elimination of HAS after repeated infusions].

Authors:  J M Mishler; M Beez
Journal:  Infusionsther Klin Ernahr       Date:  1979-04
View more
  9 in total

Review 1.  Pharmacokinetics of hydroxyethyl starch.

Authors:  Cornelius Jungheinrich; Thomas A Neff
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies.

Authors:  Romuald Bellmann; Clemens Feistritzer; Christian J Wiedermann
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

3.  Interference by hydroxyethyl starch used for vascular filling in latex agglutination test for cryptococcal antigen.

Authors:  L Millon; T Barale; M C Julliot; J Martinez; G Mantion
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

4.  Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxethy starch (HES 200/0.62, 6%).

Authors:  A C Degrémont; M Ismaïl; M Arthaud; B Oulare; O Mundler; M Paris; J F Baron
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

5.  [Comparative study of low molecular dextran or hydroxyethyl starch as a volume substitute in hemodilution therapy].

Authors:  H Kiesewetter; F Jung; J Blume; B Bulling; R P Franke
Journal:  Klin Wochenschr       Date:  1986-01-02

6.  Pharmacokinetics and Tolerability of a New Hydroxyethyl Starch (HES) Specification [HES (130/0.4)] after Single-Dose Infusion of 6% or 10% Solutions in Healthy Volunteers.

Authors:  J Waitzinger; F Bepperling; G Pabst; J Opitz; M Müller; J François Baron
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 7.  Clinical pharmacokinetic considerations in the use of plasma expanders.

Authors:  U Klotz; H Kroemer
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

8.  Haemodilution therapy in ischaemic stroke: plasma concentrations and plasma viscosity during long-term infusion of dextran 40 or hydroxyethyl starch 200/0.5.

Authors:  H Kroemer; A Haass; K Müller; H Jäger; E M Wagner; P Heimburg; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 9.  Hydroxyethyl starch based smart nanomedicine.

Authors:  Huimin Wang; Hang Hu; Hai Yang; Zifu Li
Journal:  RSC Adv       Date:  2021-01-14       Impact factor: 3.361

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.